Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 14 recruiting now full pipeline

Keratoconus: full-pipeline trial registry

14 of 22 indexed Keratoconus trials are currently recruiting.

Corpus placement: #756 of 28,707 conditions by registered trial count.

22 US clinical trials · 14 currently recruiting · #756 of 28,707 conditions by registered trial count

Keratoconus: 22 US clinical trials tracked, 14 recruiting.

Keratoconus is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Oregon Health and Science University, running 3 of these trials.

Enrollment posture brief

Registry condition keratoconus

OPEN 14 | RECR 64% | LATE 5 | EARLY 6 | RANK #756 | SPON 3

Nearest open-share peer: Autoimmune Disease (64% recruiting · 11 trials)

Keratoconus (this)64%Advanced Melanoma63.6%Acute Myeloid Leukemia Arisi18.2%Adenocarcinoma of the Prosta0%Adult Acute Myeloid Leukemia0%
Open-enrollment share among volume-matched conditions near Keratoconus

Keratoconus lists 14 open slots (64% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Keratoconus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Keratoconus is recruiting above its size-band peers.

    14 of 22 indexed trials (63.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Keratoconus trials is spread across many organizations.

    Oregon Health and Science University accounts for 3 of 22 trials (13.6%). 17 distinct sponsors appear on at least one study for this condition label.

  3. Typical Keratoconus enrolment sits around 236 participants.

    Median target enrolment is 236 among the 22 trials that report a genuine target (sentinel values excluded). 5 of those (22.7%) plan for fewer than 100 participants.

  4. Keratoconus research is mostly interventional.

    16 interventional and 6 observational studies make up this index (72.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 35

Open and recent trials

22 total, page 1 of 1

RECRUITING 20,000 participants

The K-Map Study, Global Prevalence of KC

University Hospital, Geneva

NCT03115710

RECRUITING Phase 2 510 participants

Comparison of Standard vs. Accelerated Corneal Crosslinking

Price Vision Group

NCT03922542

RECRUITING Phase 2 500 participants

Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia

Goodman Eye Center

NCT04094090

RECRUITING Phase 3 485 participants

Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases

Woolfson Eye Institute

NCT07124910

RECRUITING 445 participants

OCT in Diagnosis of Irregular Corneas

Oregon Health and Science University

NCT03504800

RECRUITING Phase 2 300 participants

Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning

Cohen Laser and Vision Center

NCT05516004

RECRUITING 258 participants

Scleral Lens Fitting Using Wide-Field OCT

Oregon Health and Science University

NCT04570020

RECRUITING Phase 3 225 participants

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

Woolfson Eye Institute

NCT07135167

RECRUITING 168 participants

A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia

Massachusetts General Hospital

NCT02118922

RECRUITING NA 100 participants

Collagen Cross-linking in Keratoconus

Oregon Health and Science University

NCT03760432

RECRUITING Phase 2 100 participants

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Glaukos Corporation

NCT07400952

RECRUITING 60 participants

Corneal Elastography and Patient Specific Modeling

The Cleveland Clinic

NCT03030755

RECRUITING 60 participants

fMRI and IVCM Cornea Microscopy of CXL in Keratoconus

Boston Children's Hospital

NCT04439552

RECRUITING NA 25 participants

Intacs Prescription Inserts for Keratoconus Patients

University of Texas Southwestern Medical Center

NCT02138669

ACTIVE NOT RECRUITING Phase 3 400 participants

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus

Epion Therapeutics

NCT06100952

ACTIVE NOT RECRUITING Phase 3 400 participants

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Epion Therapeutics

NCT06100939

ACTIVE NOT RECRUITING NA 100 participants

McNeel Eye Center Corneal Crosslinking Study

McNeel Eye Center

NCT02921009

ACTIVE NOT RECRUITING NA 100 participants

Wavefront Guided Scleral Lenses for Keratoconus and Irregular Astigmatism

Cornea and Laser Eye Institute

NCT04698590

ACTIVE NOT RECRUITING NA 32 participants

Initial Correction Keratoconus

University of Illinois at Chicago

NCT04918316

COMPLETED Phase 1 249 participants

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

Cornea Associates of Texas

NCT04667572

COMPLETED Phase 3 236 participants

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

Glaukos Corporation

NCT01344187

COMPLETED Early Phase 1 36 participants

Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus

Illinois College of Optometry

NCT04418999

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 5

Named interventions

Most-linked intervention names on Keratoconus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo and sham treatment Combination
2 trials
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment Combination
2 trials
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution Combination
2 trials
Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly Drug
1 trials
dexamethasone ophthalmic insert 0.4 mg, for intracanalicular use Drug
1 trials
KXL System Device
1 trials
placebo solution Drug
1 trials
riboflavin solution Drug
1 trials

US sites by state

Facility locations filed on Keratoconus trials. A trial with sites in several states counts in each.

Ohio 5 trials
Massachusetts 5 trials
California 5 trials
Texas 4 trials
Oregon 4 trials
Illinois 4 trials
Tennessee 3 trials
North Carolina 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Keratoconus page

22 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Keratoconus condition card totals 22 registered trials; most-linked intervention Placebo and sham treatment; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.